Rizatriptan Benzoate
Product Images NDC 54868-6397

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 54868-6397). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rizatriptan Benzoate Orally Disintegrating Tablets 10 mg Bottle Labels (54868 6397 1)

This is a description of a medication label. The medication is Rizatriptan 16mg orally disintegrating tablet, distributed by Physicians Total Care with the lot number 8860 and an expiration date of 81/68. The NDC code is provided as 54B68-G397-1.*

FDA Label Image

Rizatriptan Benzoate Structural Formula (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 01)

This text represents the chemical formula for a carboxyl group, which is composed of one carbon atom (C), two oxygen atoms (O), and one hydrogen atom (H). It is a functional group commonly found in organic molecules such as amino acids and fatty acids.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 02)

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 03)

This appears to be a graph or chart displaying the estimated probability of remedication or rescue alongside the hours post-dose for different tablets. The tablets include placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg. The estimated probability ranges from 0% to 100%.*

FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 04)

The text contains a graph showing the estimated probability of response to different treatments over time. The treatments include a placebo and orally disintegrating tablets of Rizabiptan Benzoate at two different doses (5mg and 10mg). The X-axis is labeled as "hours post-dose", and the Y-axis shows the estimated probability of response in percentage (ranging from 0% to 100%).*

FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (A20b9f51 Ea3c 420a 8ce9 A4a1da161464 05)

This is a graph showing the estimated probability of remedication or rescue for placebo and two types of orally disintegrating tablets (5mg and 10mg) of Rizatriptan Benzoate over a period of 24 hours post-dose. The graph indicates the percentage likelihood of remedication or rescue at different points in time after taking the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.